Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of “Buy” from Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have received a consensus rating of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $23.80.

Several brokerages have recently commented on LXEO. Royal Bank of Canada restated an “outperform” rating and issued a $24.00 price objective on shares of Lexeo Therapeutics in a research report on Tuesday. HC Wainwright upped their price target on Lexeo Therapeutics from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Leerink Partners reduced their price objective on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 13th. Finally, Chardan Capital boosted their target price on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th.

Lexeo Therapeutics Stock Up 14.5 %

LXEO opened at $5.61 on Friday. The stock has a market cap of $185.52 million, a price-to-earnings ratio of -1.78 and a beta of 3.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. The firm’s fifty day moving average is $6.71 and its 200 day moving average is $9.31. Lexeo Therapeutics has a fifty-two week low of $4.67 and a fifty-two week high of $19.50.

Institutional Trading of Lexeo Therapeutics

A number of large investors have recently added to or reduced their stakes in LXEO. Bank of New York Mellon Corp boosted its position in shares of Lexeo Therapeutics by 12.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company’s stock valued at $510,000 after acquiring an additional 3,483 shares during the last quarter. Rhumbline Advisers lifted its position in Lexeo Therapeutics by 37.3% during the second quarter. Rhumbline Advisers now owns 13,357 shares of the company’s stock valued at $214,000 after purchasing an additional 3,627 shares during the last quarter. Values First Advisors Inc. purchased a new position in shares of Lexeo Therapeutics in the 3rd quarter worth $67,000. Charles Schwab Investment Management Inc. grew its stake in shares of Lexeo Therapeutics by 107.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 63,874 shares of the company’s stock worth $577,000 after buying an additional 33,013 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company’s stock worth $50,000 after buying an additional 3,591 shares during the last quarter. Institutional investors own 60.67% of the company’s stock.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.